Seeking Alpha
23 Jul 2026, 16:47 UTC · 1h ago
Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earnings
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
23 Jul 2026, 16:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Medpace raised its full-year 2026 revenue guidance to a range of $2.805B–$2.885B. — Upward revisions to full-year guidance are primary drivers of stock price appreciation and signal strong organic growth.
+0.80The company reported Q2 2026 revenue growth of 17.2% YoY to $707.3M and an EPS beat of $4.25. — Strong top and bottom line beats validate the company's current operational momentum.
+0.60The net book-to-bill ratio rebounded to 1.13x and the backlog conversion rate rose to 24.1%. — Improvements in these forward-looking metrics provide high visibility into future revenue streams and sustainable growth.
+0.50Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Company reported strong revenue growth, an EPS beat, and raised its full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
